YYYong Yang

Yong Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yong Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Brock E. Martin

    Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA

    1 shared publication
  • Chantal Kling

    Poxvirus & Rabies Branch, National Center for Emerging Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Division of High-Consequence Pathogens & Pathology, Atlanta, GA 30329, USA

    1 shared publication
  • Laurie Seigler

    Poxvirus & Rabies Branch, National Center for Emerging Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Division of High-Consequence Pathogens & Pathology, Atlanta, GA 30329, USA

    1 shared publication
  • Nadia F. Gallardo-Romero

    Poxvirus & Rabies Branch, National Center for Emerging Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Division of High-Consequence Pathogens & Pathology, Atlanta, GA 30329, USA

    1 shared publication
  • Todd G. Smith

    Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA

    1 shared publication
  • Victoria A. Olson

    Poxvirus and Rabies Branch, Centers for Disease Control and Prevention , Atlanta, Georgia

    1 shared publication

Latest Publications

  • Open Access

    Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception

    by Xianfu Wu, Yong Yang, Chantal Kling, Laurie Seigler, Nadia F. Gallardo-Romero, Brock E. Martin, Todd G. Smith, Victoria A. Olson

    Rabies is preventable through vaccination, but the need to mount annual canine vaccination campaigns presents major challenges in rabies control and prevention. The development of a rabies vaccine that ensures lifelong immunity and animal population management in one dose could be extremely advantageous. A nonsurgical alternative to spay/neuter is a high priority for animal welfare, but irreversible infertility in one dose has not been achieved. Towards this goal, we developed a rabies virus-vectored immunocontraceptive vaccine ERA-2GnRH, which protected against rabies virus challenge and induced >80% infertility in mice after three doses in a live, liquid-vaccine formulation (Wu et al., 2014). To improve safety and use, we formulated an inactivated vaccine in a thermo-responsive chitosan hydrogel for one-dose delivery and studied the immune responses in mice. The hydrogel did not cause any injection site reactions, and the killed ERA-2GnRH vaccine induced high and persistent rabies virus neutralizing antibodies (rVNA) in mice. The rVNA in the hydrogel group reached an average of 327.40 IU/mL, more than 200 times higher than the liquid vaccine alone. The Gonadotropin-releasing hormone (GnRH) antibodies were also present and lasted longer in the hydrogel group, but did not prevent fertility in mice, reflecting a possible threshold level of GnRH antibodies for contraception. In conclusion, the hydrogel facilitated a high and long-lasting immunity, and ERA-2GnRH is a promising dual vaccine candidate. Future studies will focus on rabies protection in target species and improving the anti-GnRH response.